Swelling Losses Haven't Held Back Gains for Ocular Therapeutix (NASDAQ:OCUL) Shareholders Since They're up 302% Over 1 Year

Simply Wall StNov 17 20:54

Scotiabank Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $22

Futu NewsNov 15 21:35 · Ratings

Ocular Therapeutix (OCUL) Gets a Buy From Scotiabank

TipRanksNov 15 20:46 · Ratings

H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $15

Futu NewsNov 15 20:33 · Ratings

Ocular Therapeutix Is Maintained at Buy by HC Wainwright & Co.

Dow JonesNov 15 20:11 · Ratings

BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $18

Futu NewsNov 15 18:34 · Ratings